This detailed mechanism confirmed that EGFR mutant NSCLC patients may benefit not only from direct tumor killing effect of EGFR-TKIs but also indirectly from immune enhancement after EGFR-TKIs treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.